The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase Ib Results
David A Sallman1, 2, Adam S. Asch3, Monzr M. Al Malki4, et al.
1 Division of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
2 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
3 Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
4 Department of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA
Program: Oral and Poster Abstracts Type: Oral Session: 637. Myelodysplastic Syndromes – Clinical Studies: Combination Therapies Hematology Disease Topics & Pathways: Diseases, AML, Biological, Antibodies, Adult, Therapies, Non-Biological, MDS, Checkpoint Inhibitors, Chemotherapy, Cell Lineage, Immune Cells, Immunotherapy, Study Population, Clinically Relevant, Myeloid Malignancies, Stem Cells Monday, December 9, 2019: 8:00 AM W311EFGH,...